Navigation Links
TRANSCEND(TM) Trial Results Presented at European Society of Cardiology Congress and Published in The Lancet
Date:8/31/2008

Landmark ARB trial investigated Micardis(R) (telmisartan) against placebo in reducing the composite endpoint of cardiovascular death, myocardial infarction, stroke and hospitalization for congestive heart failure in ACE inhibitor intolerant high-risk patients receiving current standard of care

RIDGEFIELD, Conn., Aug. 31 /PRNewswire/ -- The primary results of the TRANSCEND(TM)* trial demonstrated that treatment with MICARDIS(R) (telmisartan) 80mg in patients receiving current standard of care resulted in an 8% reduction in the composite endpoint of cardiovascular death, myocardial infarction, stroke and hospitalization for congestive heart failure. This reduction was not statistically significant (p=0.216; HR 0.92) compared to patients receiving placebo in addition to current standard of care.(1) Results of the main secondary endpoint of TRANSCEND as pre-specified in the statistical plan demonstrated that telmisartan significantly reduced the risk of cardiovascular death, myocardial infarction and stroke in high-risk cardiovascular patients by 13% compared with those patients already receiving current standard of care (p=0.048).(1) This risk reduction was achieved despite a high proportion of patients receiving proven therapies such as statins, anti-platelet agents or beta blockers. The main secondary endpoint of TRANSCEND mirrors the primary endpoint of the landmark HOPE trial.(2) A post-hoc analysis to adjust for multiplicity and overlap with primary endpoint showed a p-value of 0.068.(1) The results were presented today at the annual meeting of the European Society of Cardiology in Munich, Germany and published online in The Lancet.

In high-risk patients who cannot tolerate an angiotensin-converting enzyme (ACE) inhibitor, the TRANSCEND trial was designed to investigate potential cardiovascular risk reduction benefits using the second-generation angiotensin II receptor blocker (ARB) telmisartan. Telmisartan was compared to placebo on top of
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Israel , August 3, 2015 ... received the statistical analysis of results from a study which ... BVX-005 phase II trial which took place in 2012, provided ... exist at the time of the study- in particular the ... epidemic in the United States in ...
(Date:8/3/2015)... Minn. , Aug. 3, 2015  EnteroMedics Inc. (NASDAQ: ... neuroblocking therapy to treat obesity, metabolic diseases and other ... has been appointed to the Board of Directors, ... a Class II Director until the 2018 annual meeting ... Ms. McDougal has served in an executive capacity ...
(Date:8/3/2015)... -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE ; Sorrento) announced ... agreement to develop and commercialize multiple prespecified and undisclosed ... company for premier antibody development and manufacturing companies in ... the terms of the agreement, Sorrento will develop and ... American, European and Japanese market. Each of the mAbs ...
Breaking Medicine Technology:Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 2Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 3EnteroMedics Announces Appointment of Lori C. McDougal to the Board of Directors 2EnteroMedics Announces Appointment of Lori C. McDougal to the Board of Directors 3Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies 2Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies 3Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies 4
(Date:8/3/2015)... California (PRWEB) , ... August 03, 2015 , ... Did ... or Orange County looking for exceptional and affordable home care options which A-1 ... services are just a few of the credentials A-1 Home Care Agency ...
(Date:8/2/2015)... ... August 03, 2015 , ... ... attending and exhibiting at the Association for Healthcare Documentation Integrity’s (AHDI) conference being ... are pleased for the opportunity the AHDI conference provides us to interact with ...
(Date:8/2/2015)... ... 03, 2015 , ... For many “would be” entrepreneurs, starting a new business can prove ... afford to start a business.” Neither needs be a major obstacle. , The U.S. ... start a business and be successful. The risks of starting a business can be high ...
(Date:8/2/2015)... ... August 02, 2015 , ... Molecular biologists in New ... indicator for mesothelioma. Surviving Mesothelioma has just posted an article on the new research. ... New South Wales tested for Ki67 expression in tissue samples from 42 patients with ...
(Date:8/1/2015)... ... 2015 , ... Back packs can be dangerous? Whaaat?! , Not the danger ... havoc on a kid's spine. With school starting again, most kids will be asking ... you are aware of how to help them prevent injuries by understanding backpack safety. ...
Breaking Medicine News(10 mins):Health News:A-1 Home Care in Los Angeles and Orange County Honors Exceptional Office Staff 2Health News:A-1 Home Care in Los Angeles and Orange County Honors Exceptional Office Staff 3Health News:Career Step to Exhibit at AHDI Conference in Alexandria, Virginia on August 7-8 2Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 2Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 3Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 4Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 5Health News:Scientists Link Protein Marker with Mesothelioma Prognosis in New Study, According to Surviving Mesothelioma 2Health News:Local AlignLife Doctor Donates Time to Check Back Packs 2
... HealthDay Reporter , TUESDAY, Sept. 20 (HealthDay News) -- ... children and teens with obsessive-compulsive disorder, new research shows. ... of the Journal of the American Medical Association ... and obsessive-compulsive disorder (OCD). "[If] a child ...
... against methamphetamine and nicotine have been selected to receive ... The two scientists, Dr. Thomas Kosten, of Baylor ... the University of Connecticut, Storrs, will each receive $500,000 ... according to the National Institute on Drug Abuse (NIDA), ...
... , TUESDAY, Sept. 20 (HealthDay News) -- New research ... saved money used for diagnosis and boosted the likelihood that ... follow-up appointments. But there,s a big catch. Researchers ... to $649 on average -- compared to the usual $3,500 ...
... Health (NIH) has awarded nearly $2 million to researchers ... to develop a new class of therapeutics for treating ... project focuses on developing biomaterials capable of capturing certain ... wound sites to enhance tissue regeneration in adults. By ...
... By Maureen Salamon HealthDay Reporter , TUESDAY, Sept. ... breast, babies seem to turn out smarter when nourished with ... two new studies indicate. The studies, done in the ... the journal Pediatrics , found that higher levels of ...
... Foundation,s Discovery Campaign, which seeks to further the growth ... announced a major corporate pledge to that initiative. St. ... Medical, has pledged $100,000 and is a "Pioneer" level ... strengthens SIR Foundation,s Discovery Campaign as it paves the ...
Cached Medicine News:Health News:Adding Psychotherapy to Meds Helps Kids With OCD 2Health News:NIDA Avant-Garde-Medications Development Award winners announced 2Health News:MRI Can Spot Breast Cancer in High-Risk Women: Study 2Health News:Transformative NIH grant will support development of tissue regeneration therapeutics 2Health News:Transformative NIH grant will support development of tissue regeneration therapeutics 3Health News:Can Fatty Acids in Breast Milk or Formula Make Kids Smarter? 2Health News:Can Fatty Acids in Breast Milk or Formula Make Kids Smarter? 3Health News:Society of Interventional Radiology Foundation accepts St. Jude Medical Foundation gift 2
Versatility of the DFS Standard Fixator provides unsurpassed below-the-ring correction of angular, rotational and translational deformities. Length discrepancy can be precisely corrected in 1/4mm inc...
The PreFix™ temporary fixator prepares you for any situation that requires rapid stabilization of complex fractures....
Angulation, translation and rotation. A whole different point of view. The Sheffield Ring Fixation System is a design achievement that advances the possibilities of fracture management....
For radial/ulnar translation, angulation, dorsal/volar translation, and incremental longitudinal distraction, this advanced system is appropriate when incremental adjustment provides an adjunctive me...
Medicine Products: